Business, energy, technology, markets and global industry news from Business News Today

follicular lymphoma

PharmaDeviceNews follicular lymphoma
Representative image: Tepkinly’s European approval expands bispecific antibody treatment options for adults with relapsed or refractory follicular lymphoma, potentially reshaping second-line lymphoma care.
Pharma & Biotech

Genmab and AbbVie secure EU approval for Tepkinly in relapsed follicular lymphoma

Discover how Tepkinly’s EU approval could reshape second-line follicular lymphoma treatment and the safety and access questions still ahead.

Read More
Representative image illustrating antibody-targeted therapy in lymphoma treatment, relevant to Japan’s approval of tafasitamab for relapsed follicular lymphoma.
Pharma & Biotech

Incyte’s Minjuvi combo gets Japan approval for relapsed follicular lymphoma

Incyte Biosciences Japan has secured approval from the Ministry of Health, Labour and Welfare for the use of Minjuvi (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma. This marks the first regulatory authorization in Japan for a CD19-directed therapy in this indication and introduces a novel CD19–CD20

Read More
Pharma & Biotech

What Genentech’s Lunsumio VELO approval means for relapsed follicular lymphoma treatment

FDA approves subcutaneous Lunsumio VELO for relapsed follicular lymphoma. Explore what this changes for bispecific antibodies and outpatient cancer care.

Read More